Spugnini Enrico P, Baldi Alfonso, Vincenzi Bruno, Bongiorni Franco, Bellelli Corrado, Citro Gennaro, Porrello Alessandro
SAFU Department, Regina Elena Cancer Institute, Via delle Messi d' Oro, 156, 00158, Rome, Italy.
Cancer Chemother Pharmacol. 2007 Feb;59(3):375-81. doi: 10.1007/s00280-006-0281-y. Epub 2006 Jun 29.
Feline soft tissue sarcomas are spontaneous, rapidly growing, and aggressive neoplasms that mimic their human counterpart. The purpose of this study was to evaluate the feasibility and efficacy of electrochemotherapy (ECT) in an adjuvant fashion for the treatment of feline sarcomas, and the possibility of repeated treatments in the case of recurrence. Cats with fibrosarcoma (FSA) were assigned to receive surgery or surgery plus ECT. Feline patients recruited in the ECT study were enrolled in a microscopic arm (39 patients) or a macroscopic arm (19 patients) on the basis of their tumor status (absence or presence of gross disease). Patients received local injection of bleomycin followed by bursts of eight biphasic pulses at a voltage of 1,300 V/cm for postoperative and of 800 V/cm for intraoperative treatments. The median time to recurrence was 4 months for cats treated with surgery alone, 19 months for the postoperative cohort, and 12 months for the intraoperative group. Moreover, ten patients with recurring neoplasms were retreated and experienced responses lasting 6 to 28+ months. Side effects were minimal. Of interest, the metastatic rate (1.7%) in our patients was negligible: only one cat had distant spread. The results suggest that ECT is a well tolerated and potentially useful addition to surgery in controlling high-grade sarcomas. On the basis of these results, additional evaluations are warranted in pets and in humans.
猫软组织肉瘤是自发的、生长迅速且具有侵袭性的肿瘤,与人类的同类肿瘤相似。本研究的目的是评估辅助性电化学疗法(ECT)治疗猫肉瘤的可行性和疗效,以及复发时重复治疗的可能性。患有纤维肉瘤(FSA)的猫被分配接受手术或手术加ECT治疗。ECT研究中招募的猫科动物患者根据其肿瘤状态(是否存在肉眼可见的疾病)被纳入微观组(39只)或宏观组(19只)。患者接受局部注射博来霉素,然后分别在术后以1300V/cm的电压和术中以800V/cm的电压进行8次双相脉冲电击。单独接受手术治疗的猫的复发中位时间为4个月,术后组为19个月,术中组为12个月。此外,10例肿瘤复发的患者接受了再次治疗,反应持续6至28 +个月。副作用最小。有趣的是,我们患者的转移率(1.7%)可以忽略不计:只有一只猫发生了远处转移。结果表明,ECT在控制高级别肉瘤方面是一种耐受性良好且可能有用的手术辅助治疗方法。基于这些结果,有必要在宠物和人类中进行进一步评估。